New automated insulin system tested in tiny trial

NCT ID NCT05299177

Terminated Disease control Sponsor: Imperial College London Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a system that automatically adjusts insulin delivery using a continuous glucose monitor, a smartphone app, and an insulin pump. It aimed to see if the system could help adults with type 1 diabetes spend more time with their blood sugar in a healthy range. Only one person took part, and the trial was stopped early, so the results are very limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: InControl automated insulin delivery system (smartphone app, continuous glucose monitor, and insulin pump)
What this could lead to: If successful, this could help people with type 1 diabetes manage their blood sugar more easily with less effort.
What could go wrong: This was a very small feasibility study with only 1 participant, so results may not apply to others. The trial was terminated early, so data is limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 DIABETES

Contacts and locations

Locations

Imperial College London, Imperial College Healthcare NHS Trust

London, W2 1PG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.